Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Spruce Biosciences ( (SPRB) ) is now available.
On May 28, 2025, Spruce Biosciences, Inc. entered into a Purchase Agreement with Michael Grey, the Executive Chair of the Company’s Board of Directors, to issue and sell one share of Series A Preferred Stock for $100. This transaction allows the Series A Preferred Stock to have significant voting power on any Reverse Stock Split Proposal, aligning its vote with the common stockholders’ decisions, thereby minimizing the impact of abstentions and non-votes. Additionally, Spruce Biosciences announced its 2025 Annual Meeting of Stockholders will be held on July 22, 2025, with a record date set for May 30, 2025, and provided revised deadlines for stockholder proposals.
The most recent analyst rating on (SPRB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Spruce Biosciences stock, see the SPRB Stock Forecast page.
Spark’s Take on SPRB Stock
According to Spark, TipRanks’ AI Analyst, SPRB is a Underperform.
Spruce Biosciences faces substantial financial challenges with declining revenues and persistent losses. Bearish technical indicators and unfavorable valuation metrics further weigh on the stock. The strategic acquisition of TA-ERT offers potential growth, but the financial instability remains a critical concern.
To see Spark’s full report on SPRB stock, click here.
More about Spruce Biosciences
Average Trading Volume: 1,429,133
Technical Sentiment Signal: Sell
Current Market Cap: $2.74M
For a thorough assessment of SPRB stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue